» Articles » PMID: 37709957

Risk Factors and 26-years Worldwide Prevalence of Endoscopic Erosive Esophagitis from 1997 to 2022: a Meta-analysis

Abstract

Erosive esophagitis (EE) is the part of gastroesophageal reflux disease (GERD) spectrum and may progress to esophageal adenocarcinoma. Due to its progressivity and unclear prevalence, we aim to identify the factors contributing in EE to decide the need for further examination. We performed a PRISMA 2020-based systematic search through PubMed and other resources up to June 2, 2022. Study quality was assessed using the Newcastle-Ottawa Scale (NOS). The odds ratio (OR) of each factor and worldwide prevalence of EE were measured. There are 114 observational studies included with a total of 759,100 participants. Out of 29 factors, the significant risk factors are age ≥ 60 y.o. (OR 2.03 [1.81-2.28]), White/Caucasian (OR 1.67 [1.40-1.99]), unmarried (OR 1.08 [1.03-1.14]), having GERD ≥ 5 years (OR 1.27 [1.14-1.42]), general obesity (OR 1.78 [1.61-1.98]), central obesity (OR 1.29 [1.18-1.42]), diabetes mellitus (DM) (OR 1.24 [1.17-1.32]), hypertension (OR 1.16 [1.09-1.23]), dyslipidemia (OR 1.15 [1.06-1.24]), hypertriglyceridemia (OR 1.42 [1.29-1.57]), hiatal hernia (HH) (OR 4.07 [3.21-5.17]), and non-alcoholic fatty liver disease (NAFLD) (OR 1.26 [1.18-1.34]). However, H. pylori infection (OR 0.56 [0.48-0.66]) and atrophic gastritis (OR 0.51 [0.31-0.86]) are protective towards EE. This study demonstrates that age, ethnicity, unmarried, long-term GERD, metabolic diseases, HH, and NAFLD act as risk factors for EE, whereas H. pylori infection and atrophic gastritis act as protective factors. These findings may enable a better understanding of EE and increase greater awareness to address its growing burden.

Citing Articles

Accuracy of COuGH RefluX Score as a Predictor of Gastroesophageal Reflux Disease (GERD) in Mexican Patients with Chronic Laryngopharyngeal Symptoms: A Cross-Sectional Study.

Carrillo-Rojas J, Zavala-Villegas S, Morales-Osorio G, Garcia-Garcia F, Gonzalez-Navarro M, Mendoza-Martinez V Diagnostics (Basel). 2025; 15(5).

PMID: 40075882 PMC: 11899231. DOI: 10.3390/diagnostics15050636.


Medication use and risk of reflux oesophagitis.

Ueta R, Komori S, Umemoto K, Hata M, Masuda E, Seto K BMJ Open Gastroenterol. 2024; 11(1.

PMID: 39689936 PMC: 11664347. DOI: 10.1136/bmjgast-2024-001468.


Hiatal hernia: risk factors, and clinical and endoscopic aspects in gastroscopy.

Abu-Freha N, Guterman R, Elhayany R, Yitzhak A, Hudes S, Fich A Gastroenterol Rep (Oxf). 2024; 12:goae086.

PMID: 39281268 PMC: 11398871. DOI: 10.1093/gastro/goae086.


The causal relationship between COVID-19 and ten esophageal diseases: a study utilizing Mendelian randomization.

He X, Li Y, Liu J, Yan G, Gao X, Li G Front Med (Lausanne). 2024; 11:1346888.

PMID: 38751976 PMC: 11094223. DOI: 10.3389/fmed.2024.1346888.

References
1.
Azami M, Salamati M, Ranjbar R, Sahebkar A . The association between metabolic syndrome and erosive esophagitis: A systematic review and meta-analysis. EXCLI J. 2021; 20:1532-1543. PMC: 8678055. DOI: 10.17179/excli2021-4282. View

2.
Fass R, Ofman J . Gastroesophageal reflux disease--should we adopt a new conceptual framework?. Am J Gastroenterol. 2002; 97(8):1901-9. DOI: 10.1111/j.1572-0241.2002.05912.x. View

3.
Ierardi E, Rosania R, Zotti M, Principe S, Laonigro G, Giorgio F . Metabolic syndrome and gastro-esophageal reflux: A link towards a growing interest in developed countries. World J Gastrointest Pathophysiol. 2011; 1(3):91-6. PMC: 3097951. DOI: 10.4291/wjgp.v1.i3.91. View

4.
Savarino E, Marabotto E, Bodini G, Pellegatta G, Coppo C, Giambruno E . Epidemiology and natural history of gastroesophageal reflux disease. Minerva Gastroenterol Dietol. 2017; 63(3):175-183. DOI: 10.23736/S1121-421X.17.02383-2. View

5.
Sandhu D, Fass R . Current Trends in the Management of Gastroesophageal Reflux Disease. Gut Liver. 2017; 12(1):7-16. PMC: 5753679. DOI: 10.5009/gnl16615. View